Eric Katz is President at Pharma & Healthcare Dimensions, applying public- and private-sector experience in health law and policy to address the quickly-changing landscape of health reform, Medicare coverage and FDA policy. He brings to the table a decade at Medicare headquarters (CMS) and another decade in FDA policy reform.
Eric understands the impact of health reform laws (ACA, Obamacare) and ways a new Administration might "repeal and replace" government's current role in healthcare. He can also dive into very fine details across a broad scope of government programs, such as Medicare drug reimbursement (Part D, ASP+6, ACO, 1115 waivers), bundled payment reforms (BPCI, CCJR, CEC, cancer care bundles), biosimilars and generic drugs. He Read more
Eric Katz is President at Pharma & Healthcare Dimensions, applying public- and private-sector experience in health law and policy to address the quickly-changing landscape of health reform, Medicare coverage and FDA policy. He brings to the table a decade at Medicare headquarters (CMS) and another decade in FDA policy reform.
Eric understands the impact of health reform laws (ACA, Obamacare) and ways a new Administration might "repeal and replace" government's current role in healthcare. He can also dive into very fine details across a broad scope of government programs, such as Medicare drug reimbursement (Part D, ASP+6, ACO, 1115 waivers), bundled payment reforms (BPCI, CCJR, CEC, cancer care bundles), biosimilars and generic drugs. He is a frequent national speaker on Medicare coverage concerns and policy reform.
Eric's goal running PharmaAndHealth.com is to translate today's regulations and headlines into a story line that helps clients predict tomorrow's events and weigh the factors that might drive change. Current projects (2017) include:
> impact of the Trump Administration and a new Congress on Obamacare (ACA) and Medicare;
> specialty drugs and Washington's general furor over drug price increases;
> Medicare add-on payments for new technologies in clinical laboratories and biotech products;
> trends in insurance coverage and reimbursement for specific products and targeted populations; and,
> impact of health reforms on vulnerable populations and corporate outlook.
